Johnson & Johnson, TREMFYA, Guselkumab, Crohn’s Disease, Inflammatory Bowel Disease, IBD Treatment, Clinical Trials, Phase 3 Clinical Trial, GALAXI 2, GALAXI 3, Clinical Remission

Spring House, Pennsylvania, United States, October 12, 2026 Johnson & Johnson has announced new three-year clinical data demonstrating sustained...